Soligenix CEO Discusses Upcoming Interim Analysis of Phase 3 FLASH2 Study on The BioMedWire Podcast
ByAinvest
Thursday, Mar 19, 2026 8:13 am ET1min read
SNGX--
IBN announces the latest episode of The BioMedWire Podcast featuring Dr. Christopher Schaber, CEO of Soligenix Inc. The podcast delivers dynamic interviews with industry experts in pharmaceutical and biotech advancement. Dr. Schaber discussed the upcoming interim analysis of the company's Phase 3 FLASH2 study evaluating HyBryte™ for the treatment of cutaneous T-cell lymphoma. He emphasized the company's upcoming inflection points and the broader significance of the interim and top-line data expected later this year.

Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue



Comments
No comments yet